Literature DB >> 19812908

[Principles of neoadjuvant therapy].

F Lordick1.   

Abstract

Neoadjuvant therapy is now an integral part in the treatment of locally advanced cancer of the esophagus and stomach. The mechanisms of action comprise downsizing of the primary tumor, improvement of the T and N categories and the earliest possible eradication of micrometastases. Several controlled clinical studies could show that these principles can indeed augment the rate of curative (R0) resections and can reduce the likelihood of systemic recurrences. As a consequence overall survival is improved by neoadjuvant therapy. This article summarizes how the basic principles of neoadjuvant therapy translate into clinical practice and gives a review of current developmental perspectives in this field.

Entities:  

Mesh:

Year:  2009        PMID: 19812908     DOI: 10.1007/s00104-009-1731-y

Source DB:  PubMed          Journal:  Chirurg        ISSN: 0009-4722            Impact factor:   0.955


  30 in total

1.  [Response prediction--early response evaluation. Consequences for surgical oncology].

Authors:  J R Siewert; F Lordick
Journal:  Chirurg       Date:  2006-12       Impact factor: 0.955

Review 2.  [R1 resection in the surgery of upper gastrointestinal tumors: relevance and therapeutic consequences].

Authors:  F Lordick; K Ott; A Novotny; C Schuhmacher; J R Siewert
Journal:  Chirurg       Date:  2007-09       Impact factor: 0.955

3.  [Neoadjuvant therapy for squamous cell carcinoma of the esophagus].

Authors:  F Lordick
Journal:  Chirurg       Date:  2005-11       Impact factor: 0.955

Review 4.  [Staging laparoscopy in oncology].

Authors:  H Feussner; F Härtl
Journal:  Chirurg       Date:  2006-11       Impact factor: 0.955

5.  New developments in the treatment of gastric carcinoma.

Authors:  H Wilke; P Preusser; U Fink; W Achterrath; H J Mayer; M Stahl; L Lenaz; J Meyer; J R Siewert; H Gerlings
Journal:  Cancer Treat Res       Date:  1991

6.  The clinical impact of histopathologic response assessment by residual tumor cell quantification in esophageal squamous cell carcinomas.

Authors:  Björn L D M Brücher; Karen Becker; Florian Lordick; Ulrich Fink; Mario Sarbia; Hubert Stein; Raymonde Busch; Frank Zimmermann; Michael Molls; Heinz Höfler; Jörg R Siewert
Journal:  Cancer       Date:  2006-05-15       Impact factor: 6.860

Review 7.  Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysis.

Authors:  F Fiorica; D Di Bona; F Schepis; A Licata; L Shahied; A Venturi; A M Falchi; A Craxì; C Cammà
Journal:  Gut       Date:  2004-07       Impact factor: 23.059

8.  Histomorphology and grading of regression in gastric carcinoma treated with neoadjuvant chemotherapy.

Authors:  Karen Becker; James D Mueller; Christoph Schulmacher; Katja Ott; Ulrich Fink; Raymonde Busch; Knut Böttcher; J Rüdiger Siewert; Heinz Höfler
Journal:  Cancer       Date:  2003-10-01       Impact factor: 6.860

9.  Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.

Authors:  S Lorenzen; T Schuster; R Porschen; S-E Al-Batran; R Hofheinz; P Thuss-Patience; M Moehler; P Grabowski; D Arnold; T Greten; L Müller; N Röthling; C Peschel; R Langer; F Lordick
Journal:  Ann Oncol       Date:  2009-06-23       Impact factor: 32.976

10.  Is a change in patient-reported dysphagia after induction chemotherapy in locally advanced esophageal cancer a predictive factor for pathological response to neoadjuvant chemoradiation?

Authors:  Karin Ribi; Dieter Koeberle; Jan C Schuller; Hanspeter Honegger; Arnaud Roth; Viviane Hess; Peter Moosmann; Roger von Moos; Markus Borner; Norbert Lombriser; Bernhard Pestalozzi; Thomas Ruhstaller
Journal:  Support Care Cancer       Date:  2009-02-07       Impact factor: 3.603

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.